Compare Abeona Therapeutics Inc (ABEO) vs JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.23. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | JEPQ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $61.46 |
52-Week Low | $4.17 | $53.77 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JEPQ trades at $60.16, up 1.3% with a bullish technical signal from moving averages. The ETF employs a covered call strategy on the Nasdaq-100 to generate monthly income, with recent dividends of $0.64, $0.56, and $0.59. Media coverage highlights its role in retirement portfolios but notes performance trade-offs versus pure growth ETFs.
Outlook is mixed: strong income appeal for retirees balances against capped upside in tech rallies. Key risks include underperformance in bull markets and dependence on option premiums. Investors prioritize income over capital appreciation with this strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →
